Alaunos Therapeutics Inc
TCRT3.560USD
-0.420-10.55%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.85MMarket Cap
LossP/E TTM
More Details of Alaunos Therapeutics Inc Company
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Alaunos Therapeutics Inc Info
Ticker SymbolTCRT
Company nameAlaunos Therapeutics Inc
IPO dateAug 20, 2004
CEOWeis (Holger)
Number of employees1
Security typeOrdinary Share
Fiscal year-endAug 20
Address501 E Las Olas Blvd
CityFORT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone13463554099
Websitehttps://alaunos.com/
Ticker SymbolTCRT
IPO dateAug 20, 2004
CEOWeis (Holger)
Company Executives of Alaunos Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ferdinand Groenewald
Mr. Ferdinand Groenewald
Vice President - Finance
Vice President - Finance
10.78K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.21K
--
Mr. Robert W. Postma
Mr. Robert W. Postma
Independent Director
Independent Director
--
--
Mr. Jaime W. Vieser
Mr. Jaime W. Vieser
Independent Director
Independent Director
--
--
Mr. Michael Jerman
Mr. Michael Jerman
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ferdinand Groenewald
Mr. Ferdinand Groenewald
Vice President - Finance
Vice President - Finance
10.78K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.21K
--
Mr. Robert W. Postma
Mr. Robert W. Postma
Independent Director
Independent Director
--
--
Mr. Jaime W. Vieser
Mr. Jaime W. Vieser
Independent Director
Independent Director
--
--
Mr. Michael Jerman
Mr. Michael Jerman
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 28
Updated: Fri, Nov 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vieser (Jaime W.)
1.73%
Postma (Robert W.)
1.72%
Watermill Asset Management
1.49%
BlackRock Institutional Trust Company, N.A.
0.96%
The Vanguard Group, Inc.
0.94%
Other
93.16%
Shareholders
Shareholders
Proportion
Vieser (Jaime W.)
1.73%
Postma (Robert W.)
1.72%
Watermill Asset Management
1.49%
BlackRock Institutional Trust Company, N.A.
0.96%
The Vanguard Group, Inc.
0.94%
Other
93.16%
Shareholder Types
Shareholders
Proportion
Individual Investor
4.37%
Investment Advisor
3.56%
Investment Advisor/Hedge Fund
0.72%
Hedge Fund
0.07%
Bank and Trust
0.06%
Research Firm
0.03%
Other
91.20%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
134
104.76K
4.77%
-152.44K
2025Q2
153
252.84K
13.09%
-146.73K
2025Q1
169
296.91K
17.46%
-90.28K
2024Q4
182
298.15K
18.62%
-116.62K
2024Q3
208
422.39K
26.38%
-38.04K
2024Q2
224
471.36K
29.44%
+11.94K
2024Q1
281
305.54K
19.08%
-201.69K
2023Q4
302
346.05K
21.58%
-260.76K
2023Q3
324
525.07K
33.28%
-179.72K
2023Q2
339
599.70K
37.93%
-192.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vieser (Jaime W.)
33.33K
1.52%
+3.40K
+11.36%
Jul 03, 2025
Postma (Robert W.)
33.15K
1.51%
+4.05K
+13.92%
Jul 03, 2025
Watermill Asset Management
33.33K
1.52%
+33.33K
--
Jun 24, 2025
BlackRock Institutional Trust Company, N.A.
21.35K
0.97%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
20.97K
0.96%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
15.95K
0.73%
+336.00
+2.15%
Jun 30, 2025
Groenewald (Ferdinand)
10.78K
0.49%
+10.78K
--
Aug 18, 2025
Hogue (Dale Curtis Jr.)
4.44K
0.2%
+442.00
+11.05%
Apr 30, 2025
Morgan Stanley Smith Barney LLC
1.74K
0.08%
+996.00
+133.51%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Date
Type
Ratio
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jul 16, 2024
Merger
10→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
Jan 29, 2024
Merger
15→1
FAQs
Who are the top five shareholders of Alaunos Therapeutics Inc?
The top five shareholders of Alaunos Therapeutics Inc are:
Vieser (Jaime W.) holds 33.33K shares, accounting for 1.52% of the total shares.
Postma (Robert W.) holds 33.15K shares, accounting for 1.51% of the total shares.
Watermill Asset Management holds 33.33K shares, accounting for 1.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 21.35K shares, accounting for 0.97% of the total shares.
The Vanguard Group, Inc. holds 20.97K shares, accounting for 0.96% of the total shares.
Vieser (Jaime W.) holds 33.33K shares, accounting for 1.52% of the total shares.
Postma (Robert W.) holds 33.15K shares, accounting for 1.51% of the total shares.
Watermill Asset Management holds 33.33K shares, accounting for 1.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 21.35K shares, accounting for 0.97% of the total shares.
The Vanguard Group, Inc. holds 20.97K shares, accounting for 0.96% of the total shares.
What are the top three shareholder types of Alaunos Therapeutics Inc?
The top three shareholder types of Alaunos Therapeutics Inc are:
Vieser (Jaime W.)
Postma (Robert W.)
Watermill Asset Management
Vieser (Jaime W.)
Postma (Robert W.)
Watermill Asset Management
How many institutions hold shares of Alaunos Therapeutics Inc (TCRT)?
As of 2025Q3, 134 institutions hold shares of Alaunos Therapeutics Inc, with a combined market value of approximately 104.76K, accounting for 4.77% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.32%.
What is the biggest source of revenue for Alaunos Therapeutics Inc?
In --, the -- business generated the highest revenue for Alaunos Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
